DK498585A - Immunogent kompleks, fremgangsmaade til fremstilling heraf, og anvendelse heraf som immunstimulerende middel, vacciner og reagenser - Google Patents

Immunogent kompleks, fremgangsmaade til fremstilling heraf, og anvendelse heraf som immunstimulerende middel, vacciner og reagenser Download PDF

Info

Publication number
DK498585A
DK498585A DK498585A DK498585A DK498585A DK 498585 A DK498585 A DK 498585A DK 498585 A DK498585 A DK 498585A DK 498585 A DK498585 A DK 498585A DK 498585 A DK498585 A DK 498585A
Authority
DK
Denmark
Prior art keywords
peptides
proteins
preparing
complex
reagents
Prior art date
Application number
DK498585A
Other languages
English (en)
Other versions
DK166653B1 (da
DK498585D0 (da
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Publication of DK498585D0 publication Critical patent/DK498585D0/da
Publication of DK498585A publication Critical patent/DK498585A/da
Application granted granted Critical
Publication of DK166653B1 publication Critical patent/DK166653B1/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK498585A 1984-11-01 1985-10-30 Multivalent immunogent kompleks, fremgangsmaade til fremstilling heraf, og anvendelse heraf som immunstimulerende middel, vacciner og reagenser DK166653B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8405493A SE8405493D0 (sv) 1984-11-01 1984-11-01 Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
SE8405493 1984-11-01

Publications (3)

Publication Number Publication Date
DK498585D0 DK498585D0 (da) 1985-10-30
DK498585A true DK498585A (da) 1986-05-02
DK166653B1 DK166653B1 (da) 1993-06-28

Family

ID=20357588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK498585A DK166653B1 (da) 1984-11-01 1985-10-30 Multivalent immunogent kompleks, fremgangsmaade til fremstilling heraf, og anvendelse heraf som immunstimulerende middel, vacciner og reagenser

Country Status (17)

Country Link
US (1) US5254339A (da)
EP (2) EP0180564B1 (da)
JP (2) JPH07116056B2 (da)
AT (1) ATE65186T1 (da)
AU (2) AU589915B2 (da)
CA (2) CA1275042A (da)
DE (1) DE3583485D1 (da)
DK (1) DK166653B1 (da)
ES (1) ES8701497A1 (da)
FI (1) FI86801C (da)
IE (1) IE58530B1 (da)
NO (1) NO167076C (da)
NZ (1) NZ213899A (da)
PT (1) PT81384B (da)
SE (1) SE8405493D0 (da)
WO (1) WO1987002250A1 (da)
ZA (1) ZA858157B (da)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
EP0231039B1 (en) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2598434B1 (fr) * 1986-05-12 1988-09-16 Pf Medicament Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
FR2614306B1 (fr) * 1987-04-22 1989-07-28 Pf Medicament Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant.
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
JPH049015U (da) * 1990-05-09 1992-01-27
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
AU666326B2 (en) * 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
JP4129544B2 (ja) * 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
JPH0756123A (ja) * 1993-08-20 1995-03-03 Nakanishi Opt:Kk 眼鏡フレーム
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0805855T3 (da) * 1995-01-27 2007-06-25 Genencor Int Overfladeaktivt middel-baseret enzymekstraktionsproces
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
EP0967484B1 (en) 1997-08-04 2007-05-02 Advanced Life Science Institute, Inc. Methods for detecting or assaying virus
ID29082A (id) * 1998-09-22 2001-07-26 Molecular Express Inc Komposisi liposom imunogenik
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
ES2535961T3 (es) 1999-04-09 2015-05-19 Zoetis P&U Llc Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
BR0109322A (pt) 2000-03-17 2002-12-10 Upjohn Co Materiais e métodos de vacina de salmonella
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7094351B2 (en) 2000-10-12 2006-08-22 Corcoran Robert C Purification of substances by reaction affinity chromatography
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003074068A2 (en) * 2002-03-01 2003-09-12 Trillium Therapeutics Inc. Use of soluble fgl2 as an immunosuppressant
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
JP2005535350A (ja) 2002-08-12 2005-11-24 アクゾ・ノベル・エヌ・ベー ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
EP1578443B1 (en) 2002-11-20 2011-01-12 Bestewil Holding B.V. Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
EP1755666B1 (en) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
AU2006257383A1 (en) 2005-06-16 2006-12-21 Universiteit Gent Vaccines for immunization against Helicobacter
BRPI0614119B8 (pt) 2005-07-28 2017-04-11 Pah Usa 15 Llc vacina para imunizar gatos contra calicivírus de felino
RS20080138A (en) 2005-10-07 2009-07-15 Pfizer Products Inc., Vaccines and methods to treat canine influenza
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PT2762163T (pt) 2006-12-27 2018-02-22 Zoetis Services Llc Métodos de administração de vacina
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
BRPI0821558A2 (pt) * 2007-12-21 2015-11-03 Wyeth Llc virus da estomatite vesicular atenuado geneticamente modificado, ecomposições e métodos de uso dessas
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
ES2729934T3 (es) 2009-06-22 2019-11-07 Wyeth Llc Composiciones y procedimientos para preparar composiciones inmunogénicas de conjugado de polisacárido capsular de serotipo 8 de Staphylococcus aureus
AR078601A1 (es) 2009-06-22 2011-11-23 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
CA2777159A1 (en) 2009-10-22 2011-04-28 Universitat Leipzig Detection of a circovirus in calves suffering from bovine neonatal pancytopenia
EP2560985B1 (en) 2010-04-21 2016-06-29 Pharmaq AS Nucleic acid sequences of a fish virus and the use thereof
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
DK2575870T3 (da) 2010-06-04 2017-02-13 Wyeth Llc Vaccineformuleringer
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP3272359A1 (en) 2010-07-23 2018-01-24 Novavax AB Influenza vaccine
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌orf2086抗原の非脂質化変異体
EP2635593B1 (en) 2010-11-05 2016-09-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Vaccines for preventing meningococcal infections
NO2640832T3 (da) 2010-11-15 2018-05-19
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
BR112013014302A2 (pt) 2010-12-08 2016-09-20 Neovacs vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma
MX350170B (es) 2010-12-22 2017-08-28 Wyeth Llc Composición inmunogénica estable de antígenos de staphylococcus aureus.
US20130287786A1 (en) 2010-12-29 2013-10-31 Theodorus Petrus Maria Schetters Canine babesiosis vaccine antigen
WO2012089749A1 (en) 2010-12-29 2012-07-05 Intervet International B.V. Salmonid alphavirus protein e2
EP2691111B1 (en) 2011-03-31 2017-09-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
BR112013025892B1 (pt) 2011-04-07 2021-01-19 Neovacs produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
EP3251692B1 (en) 2011-05-13 2023-09-27 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
EP2734619B1 (en) * 2011-07-20 2017-09-06 BGP Products B.V. Process for producing orthomyxoviral antigen and vaccines
AR087811A1 (es) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv Vacuna contra el staphylococcus aureus
WO2013051994A1 (en) 2011-10-03 2013-04-11 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104334187B (zh) 2012-03-09 2017-04-05 辉瑞公司 脑膜炎双球菌组合物及其方法
JP2015524802A (ja) 2012-07-27 2015-08-27 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated キメラospa分子を含む組成物およびその使用方法
CA2943263C (en) 2012-12-20 2018-12-04 Pfizer Inc. Glycoconjugation process
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
US10294277B2 (en) 2013-03-26 2019-05-21 The Pirbright Institute Stabilised FMDV capsids
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20160331829A1 (en) 2013-12-16 2016-11-17 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
CA2957472C (en) 2014-09-03 2021-10-26 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
EP3200820B1 (en) 2014-10-03 2023-07-05 Intervet International B.V. Broad-spectrum vaccine against avian reovirus
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
ES2834880T3 (es) 2015-03-10 2021-06-21 Bio Rad Laboratories Prueba combinada de sífilis treponémica y no treponémica
MX368897B (es) 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
JP6670374B2 (ja) 2015-09-03 2020-03-18 ノババックス,インコーポレイテッド 改善された安定性および免疫原性を有するワクチン組成物
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3033759C (en) 2016-08-17 2022-06-14 Pharmaq As Sea lice vaccine
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
CA3075853A1 (en) 2017-09-18 2019-03-21 Bayer Healthcare Llc Methods of inactivation of viruses using n-methylglucamide and its derivatives
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
JP2024500935A (ja) 2020-12-23 2024-01-10 ゼノセラ 抗感染受動免疫療法における、抗体依存性マクロファージ炎症誘発性サイトカインの放出を治療及び/又は予防するためのその使用のためのブタポリクローナル抗体組成物
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024153674A1 (en) 2023-01-18 2024-07-25 Novavax AB Methods of quantifying saponins present in particles comprising saponin and lipid

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
GB2104527B (en) * 1981-08-24 1985-10-02 Vilas V Likhite Antingens as immunostimulant adjuvants
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP0142192A1 (en) * 1983-10-22 1985-05-22 Akzo N.V. Preparation of immunogens consisting of antigenic determinates bound to glycoside-containing carriers
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
EP0231039B1 (en) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3617978A1 (de) * 1986-05-28 1987-12-03 Bayer Ag Verzweigte thermoplastische polycarbonate mit verbessertem schutz gegen uv-licht
US6578143B1 (en) * 1998-12-18 2003-06-10 Qualcomm Incorporated Method for negotiating weakened keys in encryption systems
FR2788649A1 (fr) * 1999-01-18 2000-07-21 Schlumberger Systems & Service Procede de chargement securise de donnees entre des modules de securite
FI20075083A0 (fi) * 2007-02-06 2007-02-06 Nokia Corp Ilmaisumenetelmä ja -laite monivuo-MIMOa varten

Also Published As

Publication number Publication date
DE3583485D1 (de) 1991-08-22
NO167076B (no) 1991-06-24
AU6475286A (en) 1987-05-05
ZA858157B (en) 1986-06-25
ES8701497A1 (es) 1986-12-01
JPH07116056B2 (ja) 1995-12-13
NO167076C (no) 1991-10-02
FI86801B (fi) 1992-07-15
US5254339A (en) 1993-10-19
IE58530B1 (en) 1993-10-06
EP0180564A2 (en) 1986-05-07
EP0242380A1 (en) 1987-10-28
AU589915B2 (en) 1989-10-26
DK166653B1 (da) 1993-06-28
PT81384B (pt) 1987-11-11
ATE65186T1 (de) 1991-08-15
CA1275042A (en) 1990-10-09
NZ213899A (en) 1988-10-28
CA1275246C (en) 1990-10-16
EP0242380B1 (en) 1991-04-03
WO1987002250A1 (en) 1987-04-23
PT81384A (en) 1985-11-01
SE8405493D0 (sv) 1984-11-01
EP0180564B1 (en) 1991-07-17
FI86801C (fi) 1992-10-26
FI854158A0 (fi) 1985-10-23
JPH0751514B2 (ja) 1995-06-05
ES548412A0 (es) 1986-12-01
EP0180564A3 (en) 1988-06-01
JPS61129136A (ja) 1986-06-17
NO854355L (no) 1986-05-02
FI854158L (fi) 1986-05-02
AU590904B2 (en) 1989-11-23
DK498585D0 (da) 1985-10-30
JPS63501078A (ja) 1988-04-21
AU4938385A (en) 1986-05-08
IE852672L (en) 1986-05-01

Similar Documents

Publication Publication Date Title
DK498585A (da) Immunogent kompleks, fremgangsmaade til fremstilling heraf, og anvendelse heraf som immunstimulerende middel, vacciner og reagenser
SE8205892D0 (sv) Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DK0743949T3 (da) Fremgangsmåde til fremstilling af endotoksinfrie eller endotoksinfattige nukleinsyrer og/eller oligonukleotider til gentera
FI883708A (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
Furukawa et al. Co-purification of galactosyltransferases from chick-embryo liver
Khan et al. Thermodynamic and kinetic analysis of carbohydrate binding to the basic lectin from winged bean (Psophocarpus tetragonolobus).
Grimbleby et al. Binding of trichloroacetic acid by protein
Shimura et al. Affinophoresis of trypsins
Ohta et al. The inhibition of Na, K-activated adenosinetriphosphatase by a large molecule derivative of p-chloromercuribenzoic acid at the outer surface of human red cell
Lee et al. Removal of unbound sodium dodecyl sulfate (SDS) from proteins in solution by electrophoresis through Triton X-100-agarose
Kimura et al. Isolation of α-connectin, an elastic protein, from rabbit skeletal muscle
Grefrath et al. Polypeptide components of an excitable plasma membrane
Shin et al. Intersubunit disulfides of the follitropin receptor.
Roberts et al. Use of galactose oxidase in the histochemical examination of mucus-secreting cells
Barraco et al. Paleobiochemical analysis of an Egyptian mummy
SLOMIANY et al. ABH‐Blood‐Group Antigens and Glycolipids of Human Saliva
Kleihauer et al. Haemoglobins of adult and foetal African elephants
Antonyuk et al. Carbohydrate specificity of lectin, purified from the fruiting bodies of Mycena pura/Fr./Kumm. and its use in histochemical investigation
Chatterji et al. Site of action of RNase I on the 50 S ribosome of Escherichia coli and the association of the enzyme with the partially degraded subunit.
CN104730236A (zh) 一种蛋白质固定试剂及其应用
Alvarado Quiroz Characterization of marine exopolymeric substance (EPS) responsible for binding of thorium (IV) isotopes
Wallach et al. Membrane “Macromolecules”
Rayet Analysis of the aminoglycosides neomycin and streptomycin
Omi et al. Method for detecting the lectin activity of Momordica charantia transferred from micro two-dimensional electrophoretic gel on to nitrocellulose
Ko Some properties and function of ribosomal proteins from the seeds of Pinus lambertiana

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired